Recursion Pharmaceuticals, Inc. (BMV:RXRX)
Mexico
· Delayed Price · Currency is MXN 89.00
+5.01 (5.96%)
At close: Dec 4, 2025
Recursion Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 43.69 | 58.84 | 44.58 | 39.84 | 10.18 | 3.96 | Upgrade
|
| Revenue Growth (YoY) | -32.98% | 32.00% | 11.88% | 291.46% | 156.89% | 70.85% | Upgrade
|
| Cost of Revenue | 547.14 | 359.66 | 283.81 | 203.97 | 135.27 | 63.32 | Upgrade
|
| Gross Profit | -503.45 | -300.82 | -239.24 | -164.13 | -125.09 | -59.36 | Upgrade
|
| Selling, General & Admin | 214.27 | 178.18 | 110.82 | 81.6 | 57.68 | 25.26 | Upgrade
|
| Operating Expenses | 214.27 | 178.18 | 110.82 | 81.6 | 57.68 | 25.26 | Upgrade
|
| Operating Income | -717.72 | -479 | -350.06 | -245.73 | -182.78 | -84.62 | Upgrade
|
| Interest Expense | -2.43 | -1.57 | -0.1 | -0.06 | -2.95 | -1.36 | Upgrade
|
| Interest & Investment Income | 21.16 | 15.76 | 19.12 | 6.25 | 0.07 | 0.34 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.86 | 0.03 | -1.09 | 0.05 | 0 | -0.48 | Upgrade
|
| EBT Excluding Unusual Items | -709.84 | -464.79 | -332.13 | -239.48 | -185.65 | -86.12 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.83 | -0.88 | Upgrade
|
| Pretax Income | -715.69 | -464.79 | -332.13 | -239.48 | -186.48 | -87.01 | Upgrade
|
| Income Tax Expense | -0.15 | -1.13 | -4.06 | - | - | - | Upgrade
|
| Net Income | -715.54 | -463.66 | -328.07 | -239.48 | -186.48 | -87.01 | Upgrade
|
| Net Income to Common | -715.54 | -463.66 | -328.07 | -239.48 | -186.48 | -87.01 | Upgrade
|
| Shares Outstanding (Basic) | 401 | 274 | 208 | 176 | 125 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 401 | 274 | 208 | 176 | 125 | 22 | Upgrade
|
| Shares Change (YoY) | 63.30% | 31.92% | 18.41% | 40.04% | 475.48% | 0.98% | Upgrade
|
| EPS (Basic) | -1.78 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | Upgrade
|
| EPS (Diluted) | -1.78 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | Upgrade
|
| Free Cash Flow | -447.69 | -372.87 | -299.74 | -120.58 | -198.41 | -51.23 | Upgrade
|
| Free Cash Flow Per Share | -1.12 | -1.36 | -1.44 | -0.69 | -1.58 | -2.35 | Upgrade
|
| Operating Margin | -1642.79% | -814.09% | -785.33% | -616.74% | -1795.79% | -2135.66% | Upgrade
|
| Profit Margin | -1637.81% | -788.02% | -735.99% | -601.05% | -1832.18% | -2196.01% | Upgrade
|
| Free Cash Flow Margin | -1024.72% | -633.71% | -672.43% | -302.64% | -1949.42% | -1293.03% | Upgrade
|
| EBITDA | -640.54 | -442.51 | -325.66 | -233.97 | -174.37 | -80.67 | Upgrade
|
| D&A For EBITDA | 77.17 | 36.49 | 24.4 | 11.76 | 8.41 | 3.94 | Upgrade
|
| EBIT | -717.72 | -479 | -350.06 | -245.73 | -182.78 | -84.62 | Upgrade
|
| Revenue as Reported | 43.69 | 58.84 | 44.58 | 39.84 | 10.18 | 3.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.